|1.||Kumada, Hiromitsu: 44 articles (06/2014 - 01/2002)|
|2.||Suzuki, Fumitaka: 41 articles (06/2014 - 01/2002)|
|3.||Lai, Ching-Lung: 36 articles (06/2014 - 07/2002)|
|4.||Akuta, Norio: 34 articles (06/2014 - 01/2002)|
|5.||Suzuki, Yoshiyuki: 33 articles (06/2014 - 01/2002)|
|6.||Kobayashi, Masahiro: 33 articles (06/2014 - 01/2002)|
|7.||Ikeda, Kenji: 33 articles (06/2014 - 01/2002)|
|8.||Arase, Yasuji: 32 articles (06/2014 - 01/2002)|
|9.||Liaw, Yun-Fan: 29 articles (05/2015 - 04/2002)|
|10.||Hosaka, Tetsuya: 29 articles (06/2014 - 01/2003)|
|1.||Chronic Hepatitis B
01/01/2002 - "However, durable posttreatment remission of chronic hepatitis B has not been shown to occur in a significant number of lamivudine-treated patients. "
07/01/2001 - "A long-term follow-up study was carried out to evaluate the tolerability and efficacy of long-term therapy (1 to 3 years) with high doses (150 or 300 mg daily) of lamivudine for chronic hepatitis B. "
04/01/2009 - "Anti-HBV therapeutic trials in Asia have shown that AE of chronic hepatitis B (CH-B) may result in increased sustained remission (SR) rate with lamivudine monotherapy. "
06/01/2007 - "The aim of this study was to compare the efficacy of lamivudine therapy between chronic hepatitis B (CHB) patients, whose ALT levels less than 2 times the upper limit of normal (ULN) and patients whose ALT levels are more than 2 times ULN. "
04/01/2005 - "The major aim of our study was the assessment of the efficacy of lamivudine therapy in children with chronic hepatitis B (CHB). "
08/01/2000 - "Lamivudine is highly effective in suppressing hepatitis B viral replication and hepatic necroinflammatory activity. "
02/01/2014 - "Considering the limited potency and high resistance rates to lamivudine therapy, our study emphasizes the use of more potent drugs in the management of chronic hepatitis B in the Indian subcontinent."
12/01/2011 - "This analysis suggests that supplemental use of lamivudine in mothers with high hepatitis B viraemia is effective in reducing vertical transmission and may be cost effective, from a Taiwanese societal perspective, compared with the routine active-passive immunization without lamivudine."
03/01/2009 - "Hepatitis B was treated successfully with lamivudine. "
03/01/2009 - "The obtained results suggest significant efficacy of lamivudine in patients with subacute hepatitis B. "
01/01/2006 - "However, a combination of lamivudine and siRNA-M184V was very effective in inhibiting replication of both wild-type and variant M184V viruses in mixed infection experiments. "
02/01/1999 - "Lamivudine has proven to be very effective in the treatment of both de novo and recurrent HBV infection after OLTx; however, resistance can develop. "
02/01/2001 - "Recently, Lamivudine has been licensed for use against HBV infection with good results. "
01/01/2004 - "Lamivudine is effective in the treatment of HBV infection in the dialysis setting. "
03/01/2002 - "In vitro and in vivo prophylactic and therapeutic efficacy of AZT/3TC treatment was evaluated against feline immunodeficiency virus (FIV) infection. "
12/01/2002 - "Although several clinical trials have suggested that lamivudine treatment can be very effective in patients with decompensated HBV-associated cirrhosis, its role and clinical efficacy are still uncertain because of the study designs. "
04/01/2007 - "It has been statistically proven that the efficacy of lamivudine therapy correlates with degree of fibrosis and higher histological activity index values. "
09/01/2003 - "Significant improvement in liver histology, both necroinflammation and fibrosis, can be obtained in the majority of patients treated with lamivudine for one year."
01/01/2003 - "One-year of Lamivudine treatment significantly improved necroinflammation and reduced the progression of fibrosis and the histologic activity index. "
07/01/2000 - "One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. "
03/01/2009 - "Lamivudine has been established as a safe and effective antiviral agent for the treatment of chronic HBV hepatitis. "
02/01/2006 - "The aim of this study was to evaluate the efficacy of preemptive lamivudine therapy in reducing hepatitis due to HBV reactivation in patients with HCC undergoing transarterial chemo-lipiodolization (TACL) and to seek predictors of this event. "
01/01/2004 - "Among patients with hepatitis reactivation, two were treated with lamivudine resulting in dramatic improvement and clinical remission of the disease. "
09/01/2015 - "The aim of the present study was to determine the prevalence of precore and lamivudine drug resistance mutations in lamivudine treated patients with chronic B hepatitis. "
07/01/2014 - "Lamivudine-withdrawal hepatitis was not detected; however, one case of breakthrough HBV reactivation during lamivudine treatment was observed in this study. "
|1.||Hepatitis B e Antigens
|4.||adefovir dipivoxil (Hepsera)
|8.||DNA (Deoxyribonucleic Acid)
|10.||Interferon-alpha (Interferon Alfa)
|2.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)